Alzamend Neuro
ALZN

$2.02

1.48%

Market Cap: $1.7M

About: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Employees: 7

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

23% more funds holding

Funds holding: 13 [Q1] → 16 (+3) [Q2]

0.82% less ownership

Funds ownership: 5.63% [Q1] → 4.82% (-0.82%) [Q2]

61% less capital invested

Capital invested by funds: $387K [Q1] → $150K (-$236K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ALZN.

See Analyst Rankings

Financial journalist opinion

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Monday, Alzamend Neuro Inc. ALZN stock is trading higher after the company partnered with Massachusetts General Hospital as its contract research organization.

Alzamend Neuro Stock Jumps After Post Traumatic Stress Disorder Study Pact: Details

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease (“Alzheimer's”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it is partnering with Massachusetts General Hospital as its contract research organization (“CRO”) to conduct first of its kind Phase II clinical study of AL001.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

ATLANTA--(BUSINESS WIRE)---- $ALZN #10_day_termination_process_started--Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program.

Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ATLANTA--(BUSINESS WIRE)---- $ALZN #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

See News Rankings